Enhancing Escin's Therapeutic Efficacy: A Nanoformulation Approach for Improved Stability and Anticancer Potential

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Escin, a natural compound, shows therapeutic potential but lacks effective delivery systems.
• Cellulose nanofibers (CNF) offer a biodegradable and biocompatible platform for drug encapsulation.
• Developing targeted drug delivery systems is crucial for improving cancer treatment efficacy and reducing side effects.

Purpose of the Study:

• To develop and characterize an advanced nanoformulation integrating escin with cellulose nanofibers (CNF).
• To investigate the anticancer potential, drug release kinetics, and cellular mechanisms of the CNF-escin nanoformulation.
• To evaluate the selective cytotoxicity of the nanoformulation against cancer cells compared to normal cells.

Main Methods:

• Synthesis and characterization of escin-loaded CNF using spectroscopy (UV-Vis, FTIR) and microscopy (SEM, EDX).
• In vitro drug release studies under varying pH conditions to assess release profiles.
• Cytotoxicity assays on cancer cell lines (A549, HepG2) and normal cells (L132).
• Assessment of cancer cell migration, mitochondrial membrane potential (MMP), ROS generation, and apoptosis.

Main Results:

• Successful incorporation and uniform distribution of escin within CNF were confirmed, with strong encapsulation and sustained release properties (binding energy -8.4 kcal/mol, Ki 6.88 × 10⁻⁷ M).
• Optimized formulation (10:3 drug-to-CNF ratio) exhibited controlled, prolonged escin release, especially at acidic pH, unlike free escin.
• CNF-escin nanoformulation demonstrated selective cytotoxicity against A549 and HepG2 cancer cells with minimal toxicity to L132 normal cells.
• The nanoformulation significantly reduced cancer cell migration, proliferation, and induced ROS-mediated apoptosis.

Conclusions:

• Escin-loaded CNF represents a novel, optimized drug delivery system with sustained and targeted release capabilities.
• The nanoformulation exhibits selective anticancer activity, inducing apoptosis through ROS generation and affecting MMP.
• This advanced CNF-escin nanoformulation shows significant promise as a targeted cancer therapy option.